BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 27933342)

  • 1. Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.
    Rogatko-Koroś M; Mika-Witkowska R; Bogunia-Kubik K; Wysoczańska B; Jaskuła E; Kościńska K; Nestorowicz K; Dziopa J; Szlendak U; Gwozdowicz S; Graczyk-Pol E; Lange A; Nowak J
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):63-71. PubMed ID: 27933342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Komarnicki M; Gil L; Czyż A; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange AA;
    Am J Hematol; 2014 Oct; 89(10):E176-83. PubMed ID: 25044365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
    Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of donor HLA class I mismatch, KIR-ligand mismatch and HLA:KIR pairings in hematological malignancy relapse after unrelated hematopoietic stem cell transplantation.
    Graczyk-Pol E; Rogatko-Koros M; Nestorowicz K; Gwozdowicz S; Mika-Witkowska R; Pawliczak D; Zubala M; Szlendak U; Witkowska A; Tomaszewska A; Nasilowska-Adamska B; Szczepinski A; Wojcik M; Halaburda K; Nowak J
    HLA; 2018 Dec; 92 Suppl 2():42-46. PubMed ID: 30168290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.
    Nowak J; Witkowska A; Rogatko-Koroś M; Malinowska A; Graczyk-Pol E; Nestorowicz-Kałużna K; Flaga A; Szlendak U; Wnorowska A; Gawron A
    HLA; 2024 Feb; 103(2):e15364. PubMed ID: 38312022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
    Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
    Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of KIR2DS4 gene on clinical outcome after hematopoietic stem cell transplantation.
    Burek Kamenaric M; Stingl Jankovic K; Grubic Z; Serventi Seiwerth R; Maskalan M; Nemet D; Mikulic M; Zunec R
    Hum Immunol; 2017 Feb; 78(2):95-102. PubMed ID: 27998801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients benefit from the addition of KIR repertoire data to the donor selection procedure for unrelated haematopoietic stem cell transplantation.
    Schellekens J; Rozemuller EH; Petersen EJ; van den Tweel JG; Verdonck LF; Tilanus MG
    Mol Immunol; 2008 Feb; 45(4):981-9. PubMed ID: 17881057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
    Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
    Front Immunol; 2020; 11():584520. PubMed ID: 33542712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.
    Neuchel C; Fürst D; Niederwieser D; Bunjes D; Tsamadou C; Wulf G; Pfreundschuh M; Wagner E; Stuhler G; Einsele H; Schrezenmeier H; Mytilineos J
    PLoS One; 2017; 12(1):e0169512. PubMed ID: 28107369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
    Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
    Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
    Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
    Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of donor full-length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT.
    An K; Li B; Luo C; Wang J; Luo C; Chen J
    Pediatr Transplant; 2020 Sep; 24(6):e13728. PubMed ID: 32594584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
    Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.